5 Body Composition Changes People Notice on Ozempic/Wegovy

The STEP clinical trial program for semaglutide (the active ingredient in both Ozempic and Wegovy) produced some of the most significant weight loss results ever seen in a pharmaceutical trial. But weight loss is not a single phenomenon. What you lose, fat versus muscle versus water, and where you lose it, visceral versus subcutaneous fat, profoundly affects your health outcomes. Here is what the research and patient experiences reveal.

Visceral Fat Decreases Significantly, Often More Than Subcutaneous Fat

Visceral fat, the deep abdominal fat that wraps around your organs, is the most metabolically dangerous type of fat. A study published in The Lancet Diabetes and Endocrinology using DEXA and MRI scans found that semaglutide reduced visceral fat by 30 to 40 percent, a proportionally larger reduction than subcutaneous fat. This is excellent news because visceral fat is the primary driver of insulin resistance, systemic inflammation, and cardiovascular disease. Patients often notice this as a significant reduction in waist circumference even before the scale moves dramatically. Clinically, this visceral fat reduction is why GLP-1 drugs improve metabolic markers far beyond what weight loss alone would predict.

Why it matters for your metabolic age: Visceral fat reduction is one of the most powerful ways to improve blood pressure and blood sugar simultaneously, producing dramatic metabolic age improvements.

Lean Muscle Mass Decreases, Which Requires Active Intervention

The STEP 1 trial found that approximately 39 percent of total weight lost on semaglutide came from lean mass. For someone who loses 30 pounds, that means roughly 12 pounds of muscle. This is a significant concern because muscle loss reduces your resting metabolic rate by about 6 calories per day per pound, lowers your glucose disposal capacity, and increases your risk of weight regain. Patients who do not engage in resistance training often describe feeling “smaller but softer” rather than “leaner and stronger.” The phenomenon has been nicknamed “Ozempic face” and “Ozempic body” in popular media, describing the loose, deflated appearance that comes from losing both fat and muscle quickly.

Why it matters for your metabolic age: Muscle loss can partially offset the blood sugar improvements from fat loss, which means your metabolic age may not improve as much as your weight loss would suggest without resistance training.

Body Fat Percentage Improves but May Not Change as Much as Expected

Because GLP-1 drugs cause both fat and muscle loss, your body fat percentage may not improve as dramatically as you might expect. If you lose 20 pounds of fat and 10 pounds of muscle, your body fat percentage changes less than if you had lost 30 pounds of pure fat. A study from the journal Obesity found that patients on semaglutide who also performed resistance training had significantly better body fat percentage improvements than those on medication alone. The takeaway is that the drug handles the appetite suppression, but your lifestyle determines the quality of the weight loss.

Waist-to-Hip Ratio Improves as Central Adiposity Decreases

GLP-1 drugs appear to preferentially reduce central (abdominal) fat. Research from the SURMOUNT trial for tirzepatide found that waist circumference decreased by an average of 7 inches in the highest dose group. This is a clinically significant change because waist-to-hip ratio is independently associated with cardiovascular disease risk. Patients frequently report needing entirely new wardrobes within 6 to 12 months of treatment. The abdominal fat loss is typically the first visible change and occurs before significant changes in the arms, legs, or face.

Skin and Facial Changes Become Noticeable With Rapid Weight Loss

Rapid weight loss from any cause, including GLP-1 drugs, can result in loose skin, especially in people over 40 or those who lose more than 50 pounds. The loss of both subcutaneous fat and collagen support in the face leads to the widely discussed “Ozempic face,” characterized by hollowed cheeks, more visible wrinkles, and a gaunt appearance. A study from the Aesthetic Surgery Journal found that patients seeking facial rejuvenation procedures after GLP-1 weight loss increased by 40 percent between 2022 and 2024. Slower weight loss, adequate protein intake, hydration, and potential dermatological consultation can mitigate some of these effects.

Why it matters for your metabolic age: While cosmetic changes can be concerning, the underlying metabolic improvements from fat loss, especially visceral fat, represent genuine health gains reflected in a lower metabolic age.

Track Your Metabolic Improvements Beyond the Scale

Body composition changes on GLP-1 drugs are complex. The scale tells only part of the story. Penlago’s free MetaAge calculator captures the metabolic improvements by using blood pressure, blood sugar, BMI, and age to calculate your metabolic age in 60 seconds. Track it throughout your treatment to see the full health picture.

Find out your metabolic age in 60 seconds – free.